Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.2M Buy
60,465
+15,907
+36% +$3.42M 0.32% 59
2026
Q1
$9.69M Buy
44,558
+7,990
+22% +$1.77M 0.26% 75
2025
Q4
$8.36M Buy
36,568
+6,646
+22% +$1.51M 0.27% 65
2025
Q3
$6.93M Buy
29,922
+5,236
+21% +$1.07M 0.32% 61
2025
Q2
$4.58M Buy
24,686
+4,450
+22% +$827K 0.31% 58
2025
Q1
$4.24M Buy
20,236
+2,508
+14% +$488K 0.43% 44
2024
Q4
$3.15M Buy
17,728
+8,140
+85% +$1.5M 0.38% 46
2024
Q3
$1.89M Buy
9,588
+3,595
+60% +$671K 0.38% 57
2024
Q2
$1.03M Buy
5,993
+2,352
+65% +$390K 0.34% 69
2024
Q1
$663K Buy
3,641
+1,346
+59% +$232K 0.38% 69
2023
Q4
$356K Buy
+2,295
New +$335K 0.35% 88

Other funds holding ABBV

Savvy Advisors Inc's ABBV Position: Q2 2026 in Review

Savvy Advisors Inc increased its AbbVie (ABBV) stake by 36% in Q2 2026, buying an estimated $3.42M and bringing the position to 60,465 shares worth $15.2M. The position accounts for 0.32% of the portfolio, ranked #59.

Savvy Advisors Inc first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Savvy Advisors Inc held 60,465 shares of AbbVie worth $15.2M as of Q2 2026.
  • Savvy Advisors Inc bought 15,907 AbbVie shares in Q2 2026, an estimated $3.42M.
  • AbbVie made up 0.32% of Savvy Advisors Inc's portfolio in Q2 2026, its #59 holding.
  • Savvy Advisors Inc first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Savvy Advisors Inc's 13F filing for Q2 2026, filed 3 Aug 2026.